{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.14","upperLimit":"0.52","value":"0.31"},{"groupId":"OG001","lowerLimit":"0.20","upperLimit":"0.45","value":"0.31"},{"groupId":"OG002","lowerLimit":"0.06","upperLimit":"0.38","value":"0.19"},{"groupId":"OG003","lowerLimit":"0.05","upperLimit":"0.24","value":"0.12"},{"groupId":"OG004","lowerLimit":"0.27","upperLimit":"0.53","value":"0.40"},{"groupId":"OG005","lowerLimit":"0.05","upperLimit":"0.37","value":"0.17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"58"},{"groupId":"OG005","value":"24"}],"units":"Participants"}],"description":"Tumor response rate defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to the RECIST criteria divided by the total number of efficacy evaluable patients enrolled on study. Patients were evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. In brief, a Complete Response (CR) means the complete disappearance of all target lesions and a reduction in each lymph node to \\<1 cm. A Partial Response (PR) is defined as a 30% decrease in the sum of the longest diameter of the non-nodal target lesion from baseline. Each requires no new lesions present at evaluation. The proportion of participants with a response is provided here for each cohort. The proportion was calculated as the number of patients that had a best response of CR or PR divided by the number of patients evaluated for a response in each cohort.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Endometrial Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Ovarian Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Hepatocellular Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Carcinoid Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Islet Cell (Double Agent) Cohort"},{"description":"Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Islet Cell (Bevacizumab-only) Cohort"}],"paramType":"NUMBER","populationDescription":"For this analysis, the number of patients that had a best response of CR or PR were divided by the number of patients evaluated for a response.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Tumor Response Rate","type":"PRIMARY","unitOfMeasure":"proportion of participants"}